CTLA4 and neoplasm: This suggests that, while 90Y-NM600-treated tumor cells can activate IFN-gamma production independent of tumor cell expression of STING, the beneficial effects of anti-CTLA-4 in combination with 90Y-NM600 may be STING-dependent.